The present study will aim to evaluate the efficacy of milnacipran in the treatment of pain
due to osteoarthritis (OA), that is, to determine whether milnacipran provides superior
efficacy to placebo in patients with OA. Milnacipran is a serotonin-norepinephrine reuptake
inhibitor (SNRI) that is currently approved in the United States in the treatment of major
depressive disorder and fibromyalgia. There is increased evidence to suggest that SNRIs may
be effective in the treatment of chronic pain conditions, such as OA.
The hypothesis in this study is that the survival time (time from randomization to loss of
efficacy) of milnacipran group is superior to that of placebo group.